Stock Pulse
Abbott Laboratories (ABT) is expected to announce Q1 2025 earnings on April 16th, with projected EPS of $1.07 (+9.2% YoY) and revenue of $10.42 billion (+4.5% YoY) [1], [4], [6], [10]. Analysts are bullish, upwardly revising EPS estimates and giving ABT a Zacks Rank #2 (Buy), suggesting potential market outperformance [1], [6], [10]. Growth is anticipated across most divisions, particularly Medical Devices (Diabetes Care, Structural Heart) [1], [4], but Diagnostics may decline slightly [1]. However, increased competition from Dexcom's new diabetes device poses a potential risk [5]. Despite a recent 2% stock decline, possibly related to the Dexcom news [5], [6], the longer-term outlook remains positive given consistent earnings beats and projected growth [4], [9], [10]. Institutional investors decreased holdings recently but have seen 12% gains over the past year [7].